Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
2024 · Blood Cancer Journal · 19 citations
https://doi.org/10.1038/s41408-024-01197-2
A
Al‐Ola Abdallah
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
284
Papers
2.6K
Citations
22
h-index
45
i10-index
Al‐Ola Abdallah is an academic researcher from University of Kansas Medical Center. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & CAR-T cell therapy research & Protein Degradation and Inhibitors. The author has an h-index of 22, co-authored 242 publications.
ORCID: 0000-0002-6603-185XPapers by this author
worksHospitalization at the end of life in patients with multiple myeloma
2021 · BMC Cancer · 13 citations
https://doi.org/10.1186/s12885-021-08079-x
A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma
2021 · Clinical Lymphoma Myeloma & Leukemia · 6 citations
https://doi.org/10.1016/j.clml.2021.03.006
MM-504 Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome in Relapsed and Refractory Multiple Myeloma Using the FAERS Database
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)01693-8
CT-163 Chimeric Antigen Receptor T Cell (CAR-T) Therapy Outcomes In Rheumatological Autoimmune Disorders: A Systematic Review
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)01743-9
CT-208 Efficacy of Axatilimab in the Management of Refractory Chronic Graft-Versus-Host Disease
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)01748-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat